KLRD logo with mission statement



Google:

Twitter Logo in Blue Facebook Logo
 

Back to:

2021 Special Committee on Federal 340B Drug Program





SenateHouse
Senator Renee Erickson, Vice Chairperson
Senator Beverly Gossage
Senator Richard Hilderbrand
Senator Kristen O'Shea
Senator Jeff Pittman
Senator Mary Ware
Representative Susan Concannon, Chairperson
Representative John Barker
Representative Will Carpenter
Representative Brenda Landwehr
Representative Vic Miller
Representative Sean Tarwater
Representative Kathy Wolfe Moore
 
Kansas Legislative Research Dept. Office of Revisor of Statutes
Megan Leopold
Melissa Renick
Scott Abbott
Amelia Kovar-Donohue
Eileen Ma
 
Committee Assistant

Study Topic

The Committee is directed to:

  • Review the 340B Drug Pricing Program, with the objective of gaining a better understanding of how the program is implemented in Kansas and the experience of participating entities.

Topics for review should include:

  • Federal requirements of the program;
  • The role qualifying 340B providers, pharmacies, and pharmacy benefit managers play in the program;
  • The fiscal impact of such program on all participants;
  • Any federal or state law changes affecting such program;
  • Any recent marketplace developments of interest; and
  • The impact of such program on health care payers.

[Note: Provisions in 2021 SB 159 [Section 20 (c)] directed the Legislature to create an interim study committee on the federal 340B program. The law specified the Legislative Coordinating Council would appoint a special committee comprised of 13 members, with its chairperson appointed by the Speaker of the House of Representatives.]

 

Approved Meeting Days: 2 days

Committee Archive:

KLRD logo, KLRD all caps, in blue Kansas Legislative Research Department - Room 68-W State Capitol Building, 300 SW 10th Avenue, Topeka, Kansas 66612-1504 -- Phone (785) 296-3181 -- kslegres@klrd.ks.gov